A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

被引：23
|
作者：
Javle, Milind M. [1 ]
Bridgewater, John A. [2 ]
Gbolahan, Olumide B. [3 ]
Jungels, Christiane [4 ]
Cho, May Thet [5 ]
Papadopoulos, Kyriakos P. [6 ]
Thistlethwaite, Fiona C. [7 ,8 ]
Canon, Jean-Luc Re [9 ]
Cheng Lulu [10 ]
Ioannidis, Sonia [10 ]
Gogov, Sven [10 ]
Aung, Naing [11 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] UCL, Inst Canc, London, England
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[5] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[7] Dept Med Oncol, Manchester, Lancs, England
[8] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[9] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[10] Incyte Corp, Wilmington, DE USA
[11] Univ Texas MD Anderson Canc Ctr, Phase Program 1, Dept Invest Canc Therapeut, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
    He, Xiaojun
    Tan, Kai
    Du, Xilin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS582 - TPS582
  • [42] A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Tanwandee, Tawesak
    Sukeepaisarnjaroen, Wattana
    Chan, Stephen Lam
    Choo, SuPin
    Han, Guohong
    Sriuranpong, Virote
    Pan, Hongming
    Yau, Thomas Cheung
    Ren, Zhenggang
    Xu, Jian-Ming
    Peng, Bin
    Saji, Takami
    Sun, Yongjian
    Huang, Alan
    Manenti, Luigi
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] A Randomized Phase II Study of Gemcitabine (GEM) Plus S-1 Combination Chemotherapy Versus GEM Monotherapy in Patients (pts) With Advanced Biliary Tract Cancer (BTC) - GS-COMBI Study
    Sasaki, T.
    Isayama, H.
    Ito, Y.
    Yasuda, I.
    Toda, N.
    Hanada, K.
    Matsubara, S.
    Maguchi, H.
    Yashima, Y.
    Kamada, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S470 - S470
  • [44] A phase II study of anlotinib with cediranib as a second-line treatment for patients with advanced biliary tract cancers (aBTCs).
    Zhao, Ruihua
    Zong, Hong
    Jin, Shuiling
    Zhong, Qian
    Jiang, Miao
    Jin, Ming
    Li, Rui
    Jiang, Guozhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers.
    Wheler, J. J.
    Janku, F.
    Jackson, T.
    Fu, S.
    Sun, M.
    Yang, H.
    Naing, A.
    Moulder, S. L.
    Tsimberidou, A. M.
    Hong, D. S.
    Falchook, G. S.
    Piha-Paul, S. A.
    Garcia-Manero, G.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in combination with weekly paclitaxel in patients (pts) with advanced solid cancers.
    Patnaik, A
    Mita, AC
    Izbicka, E
    Carrizales, G
    Howes, A
    Troenaru, M
    Tolcher, AW
    Zhang, S
    Berg, K
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 228S - 228S
  • [47] Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET plus NSCLC
    Bauer, Todd M.
    Schuler, Martin
    Berardi, Rossana
    Lim, Wan-Teck
    Van Geel, Robin
    De Jonge, Maja
    Azaro, Analia
    Gottfried, Maya
    Han, Ji-Youn
    Lee, Dae Ho
    Wollner, Mira
    Hong, David
    Voge, Arndt
    Delmonte, Angelo
    Krohn, Alexander
    Zhang, Yong
    Squires, Matthew
    Giovannini, Monica
    Akimov, Mikhail
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S257 - S258
  • [48] Biomarker analysis of first-line sintilimab plus gemcitabine and cisplatin in patients with advanced biliary tract cancers: Results from a phase II study.
    Yuan, Zhen-Gang
    Zeng, Tian-Mei
    Tao, Chen-Jie
    Yang, Guang
    Xu, He-Ming
    Wei, Wei
    Chen, Xi-Yun
    Cheng, Zhuo
    Dong, Yu-Long
    Shang, Pei-Pei
    Lou, Cheng
    Han, Qin
    Chen, Dong-Sheng
    Song, Yunjie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16189 - E16189
  • [49] Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Furuse, Junji
    Okusaka, Takuji
    Funakoshi, Akihiro
    Yamao, Kenji
    Nagase, Michitaka
    Ishii, Hiroshi
    Nakachi, Kohei
    Ueno, Hideki
    Ikeda, Masafumi
    Morizane, Chigusa
    Horikawa, Yuki
    Mizuno, Nobumasa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (09) : 552 - 556
  • [50] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    McDermott, D. F.
    Infante, J. R.
    Chowdhury, S.
    Voss, M. H.
    Motzer, R. J.
    Perini, R. F.
    Morosky, A.
    Zheng, F. F.
    White, B. C.
    Wang, Q.
    Jewell, R. C.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
12345